Reata sheds value as FDA reviewers doubt bardoxolone’s benefit 

Reata’s bardoxolone could be headed toward another disappointment as briefing documents released ahead of Wednesday’s advisory committee meeting said FDA reviewers aren’t convinced of the therapy’s clinical benefit in a renal indication.

In a document released Monday, FDA reviewers wrote that data in the NDA from Reata Pharmaceuticals Inc. (NASDAQ:RETA) do not establish bardoxolone methyl’s efficacy at slowing the loss of kidney function in patients with Alport syndrome and reducing the risk of progression to kidney failure. Bardoxolone’s PDUFA date is Feb. 25...